ICTS Director leads large national clinical trial that aims to expand treatment options for patients with severe COVID-19

Two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19, according to a national study led by Washington University School of Medicine in St. Louis. William G. Powderly, MD, (right) who led the large clinical trial, discusses patient conditions with Maanasi Samant, MD, in the intensive care unit at Barnes-Jewish Hospital, one of the major trial sites, during the COVID-19 pandemic.
View Content

William G. Powderly, MD hopes this study including nearly 2,000 patients in 95 hospitals across the US and Latin America will be helpful in revising guidelines for best practices in treating patients hospitalized with COVID-19, and in reducing mortality in severely ill patients.